

RECEIVED

OCT 19 2000



TECH CENTER 1600/2900
ATTORNEY DOCKET NO. 50062/004001
TECH CENTER 1600/2900

652100

Certificate of Mailing: Date of Deposit: October 12, 2000

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Barry

Printed name of person mailing correspondence

Susan M. Barry
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolorès Ludevid et al.

Art Unit: 1638

Serial No.: 09/117,246

Examiner: Zaghmout, O.

Filed: December 3, 1998

Title: AMINO ACID-ENRICHED PLANT PROTEIN RESERVES,
PARTICULARLY LYSINE-ENRICHED MAIZE γ -ZEIN, AND
PLANTS EXPRESSING SUCH PROTEINS

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed on December 3, 1998, enclosed is a sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of eight pages.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.



RECEIVED

RECEIVED

OCT 19 2000

OCT 26 2000

TECH CENTER 1500/2900

TECH CENTER 1500/2900

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the

application description and claims to refer to their respective sequences.

As required by 37 CFR 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.


As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

October 12, 2000


Kristina Bieker-Brady, Ph.D.
Reg. No. 30,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\Ntserver\documents\50062\50062.004001 Seq. Statement.wpd

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

OCT 16 2000
TRADEMARKS & TRADEMARKS
18230, May 1, 1990

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to ~~these regulations~~, published at 1114 OG 29, May 15, 1990 and at 55 FR 37 C.F.R. 1.821(e).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600



PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE